Hormonal
GLP-1 analogs exert pleiotropic effects on multiple tissues beyond glucose regulation, including neuroprotection, cardiac improvement, and metabolic reprogramming, mediated by cAMP/PKA/EPAC signaling pathways.
GLP-1 analogs (like semaglutide or liraglutide) are not just for blood sugar. They work by mimicking a natural hormone to signal your brain, heart, and gut. This leads to reduced appetite, better heart function, and potential protection for your brain and kidneys. Consistency is key because these benefits build over time through sustained receptor activation.
Both in vitro and in vivo studies have demonstrated that GLP-1 mimetics alleviate endoplasmic reticulum stress, regulate autophagy, promote metabolic reprogramming, stimulate anti-inflammatory signaling, alter gene expression, and influence neuroprotective pathways.
Why this rating
The paper is a comprehensive review citing numerous in vitro, in vivo, and clinical studies, though it notes some conflicting results in specific contexts.
Source
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Jordan Rowlands et al. · Frontiers in Endocrinology · 2018
DOI 10.3389/fendo.2018.00672
More from this paper
- GLP-1 analogs protect pancreatic beta-cells from apoptosis and ER stress by promoting autophagy and metabolic reprogramming, thereby preserving beta-cell mass in Type 2 Diabetes.Good
- GLP-1 analogs improve skeletal muscle glucose metabolism and glycogen synthesis through non-canonical signaling pathways independent of cAMP.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →